source
- Takeda and Protagonist Therapeutics receive FDA approval for rusfertide (Mimrylo) to treat polycythemia veraThe FDA approved rusfertide, to be sold as Mimrylo, for the treatment of polycythemia vera, a rare blood cancer, marking a key win for Takeda and its partner Protagonist Therapeutics. The decision…
- Eli Lilly to acquire Merida Biosciences for up to $2.875 billion, bolstering its immunology pipelineEli Lilly announced a deal to purchase Merida Biosciences, a biotech focused on immunology, for a total consideration that could reach $2.875 billion. The acquisition adds Merida's assets in fast-…